DelveInsight’s “Opioid Use Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Opioid Use Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Opioid Use Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Opioid Use Disorder treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Opioid Use Disorder: An Overview
Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction, representing the most severe form of the disorder. Opioid use disorder has serious potential consequences, including disability, relapses, and death. The Diagnostic and Statistical Manual of Mental Disorders describes opioid use disorder as a problematic pattern of opioid use leading to problems or distress.
Treatment typically involves cognitive behavioral approaches, such as encouraging motivation to change and education about treatment and relapse prevention. It often includes participation in mutual-aid organizations, such as Narcotics Anonymous. MOUD has been shown to help people stay in treatment and to reduce opioid use, opioid overdoses, and risks associated with opioid use disorder.
Opioid Use Disorder Market Key Facts
The total market size of Opioid Use Disorder (OUD) in the United States was approximately USD 1,370 million in 2022.
Spain recorded the least market share, i.e., around 2% of the total market size of Opioid Use Disorder (OUD) in the 7MM in 2022.
Among the EU4 (Germany, France, Italy, and Spain) and the UK, France had the largest revenue share in 2022.
In 2022, buprenorphine captured the largest market size of Opioid Use Disorder (OUD) in the 7MM.
The total prevalent cases of Opioid Use Disorder (OUD), in the 7MM, were approximately 3,971,300 cases in 2022 and are projected to increase during the forecast period (2023-2032).
In 2022, the United Kingdom accounted for ~474,500 prevalent cases of Opioid Use Disorder (OUD).
In 2022, it was observed that the United States accounted for ~1,184,000 cases in males and ~934,000 cases in females.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Opioid Use Disorder pipeline therapies. It also thoroughly assesses the Opioid Use Disorder market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Opioid Use Disorder drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Opioid Use Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Opioid Use Disorder epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Opioid Use Disorder epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Opioid Use Disorder Epidemiology, Segmented as –
Total Prevalent Cases of Opioid Use Disorder in the 7MM [2019-2032]
Age-Specific Cases of Opioid Use Disorder in the 7MM [2019–2032]
Severity-Specific Cases of Opioid Use Disorder in the 7MM [2019–2032]
Gender-Specific Cases of Opioid Use Disorder in the 7MM [2019–2032]
Opioid Use Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Opioid Use Disorder market or expected to be launched during the study period. The analysis covers the Opioid Use Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Opioid Use Disorder drugs based on their sale and market share.
The report also covers the Opioid Use Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Opioid Use Disorder companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Opioid Use Disorder Market Will Evolve and Grow by 2032 @
“On May 23, 2023, Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine-containing product. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI is to be administered only by healthcare providers in a healthcare setting and will be available in the U.S. in September 2023.”
Opioid Use Disorder Therapeutics Analysis
As few potential therapies are being investigated to manage Opioid Use Disorder, it is safe to predict that the treatment space will experience significant reconstitution during 2023–2032. However, the challenges of the rigid and burdensome structure of regulatory authorities will decide the fate of all these pipeline therapies and the impact they will have on overall revenue generation.
Opioid Use Disorder Companies Actively Working in the Therapeutics Market Include
Some of the leading players in the Opioid Use Disorder therapeutics market include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus, and many others.
Emerging and Marketed Opioid Use Disorder Therapies Covered in the Report Include:
CAM2038: Braeburn Pharmaceuticals
BXCL501: BioXcel Therapeutics
PROBUPHINE/SIXMO: Titan Pharmaceuticals/Molteni Farmaceuticci
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Opioid Use Disorder Competitive Intelligence Analysis
4. Opioid Use Disorder Market Overview at a Glance
5. Opioid Use Disorder Disease Background and Overview
6. Opioid Use Disorder Patient Journey
7. Opioid Use Disorder Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Opioid Use Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Opioid Use Disorder Unmet Needs
10. Key Endpoints of Opioid Use Disorder Treatment
11. Opioid Use Disorder Marketed Therapies
12. Opioid Use Disorder Emerging Drugs and Latest Therapeutic Advances
13. Opioid Use Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Opioid Use Disorder Market Outlook (In US, EU5, and Japan)
16. Opioid Use Disorder Companies Active in the Market
17. Opioid Use Disorder Access and Reimbursement Overview
18. KOL Views on the Opioid Use Disorder Market
19. Opioid Use Disorder Market Drivers
20. Opioid Use Disorder Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Autism Spectrum Disorder Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Autism Spectrum Disorder market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Autism Spectrum Disorder market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States